Transcatheter Valve Therapies (TVT)
A Multidisciplinary Heart Team Approach | June 16-18, 2016 | Sheraton Grand Chicago | Chicago, IL

June 16-18, 2016
Sheraton Grand Chicago | Chicago, IL

 

Educational Grant Support

Transcatheter Valve Therapies (TVT) 2016 is sponsored by the Cardiovascular Research Foundation and supported through educational grants from commercial supporters.

The educational grant support of our industry colleagues, who, like the Cardiovascular Research Foundation, are dedicated to educating medical professionals and the public to enhance patient outcomes, helps to make this program possible.

The Cardiovascular Research Foundation gratefully acknowledges the Transcatheter Valve Therapies (TVT) 2016

MAJOR BENEFACTORS:

Edwards Lifesciences
Medtronic, Inc.

BENEFACTORS:

Abbott
Bard Peripheral Vascular, Inc.
Boston Scientific Corporation
HLT, Inc.
Mitralign, Inc.
Siemens Healthineers
St. Jude Medical
Valtech Cardio, Ltd.


It is the policy of the Cardiovascular Research Foundation to ensure balance, independence, objectivity, and scientific rigor in all of its sponsored educational programs. Commercial support from industry does not influence educational content, faculty selection, and/or faculty presentations, and, therefore, does not compromise the scientific integrity of the educational activity.

Course Highlights:

  • Live case transmissions on transcatheter, aortic, and mitral valve therapies
  • BioSkills – anatomical demonstrations of valvular heart disease using cadaveric heart preparations
  • Advanced imaging for diagnosis and treatment of valvular heart disease
  • Updates on TVT clinical trials
  • Practical clinical workshops, therapeutic dilemmas, and how-to sessions
  • Newest transcatheter therapies in aortic, mitral, and tricuspid disease
  • Early case experiences with transcatheter mitral valve replacement

Learning Objectives:

  • Discuss evaluation and management of patients with valvular heart disease
  • Assess the imaging modalities available for diagnosis of valvular heart disease
  • Describe current and future therapeutic options for valvular heart disease
  • Acquire the skills necessary to perform transcatheter valve therapies

The product of collaboration between Drs. Martin B. Leon, Mark Reisman, Gregg W. Stone, and John G. Webb, the first TVT was held in 2007 and has since become the preeminent event in transcatheter valve therapies. We spoke with Dr. Webb about the TVT workshop and more.

Now in its seventh year, how did the idea begin for the TVT workshop?

John G. Webb, MD: At the same time that I was planning a transcatheter valve meeting in Vancouver, Mark Reisman was revisiting his annual interventional meeting in Seattle. Marty Leon and Gregg Stone proposed we join together to develop ‘Transcatheter Valve Therapies’ as the definitive transcatheter valve meeting along the lines of TCT.

How has the field changed since that first TVT in 2007?

Dr. Webb: In 2007, there were only two transcatheter heart valves, and we were all trying to figure out how to perform these procedures safely. Since then, both the technology and our understanding of it have advanced rapidly. Aortic valve implantation is now solidly established as a front line therapy for a steadily increasing number of patients and other transcatheter valve therapies are now coming online.

What are the important reasons to attend TVT?

Dr. Webb: The field continues to evolve rapidly. With that, there are new technologies, new techniques, and new insights, all of which are being discussed at TVT.

What are the long-term implications for patients with valvular disease?

Dr. Webb: Transcatheter valve procedures are set to become the dominant approach to managing valve disease. We can already see a trend from procedures only in "no option" patients to high-risk patients and now to intermediate-risk patients. In the foreseeable future, we will see this trend continue and include lower-risk patients.

TVT features live cases and Bioskills Sessions. What are the benefits of having both?

Dr. Webb: The Bioskills Sessions really help attendees understand how anatomy, technology, and technique interact together. Live cases are really about seeing how the heart team approaches different cases. The combination of live cases and Bioskills are why TVT has more of a workshop feel to it than just a conference.

Why is attendance growing year after year for TVT?

Dr. Webb: TVT has a great mix of top international faculty, great live cases, and exciting new ideas. We expect to see many new faces at TVT 2014.